YTHDC1 and urinary bladder carcinoma: It was found that, after 48 h of cisplatin treatment, cell viability was enhanced in YTHDC1 silencing bladder cancer cells, as demonstrated with IC50 for cisplatin, which increased from 46.18 ± 0.63 μM in shNC cells to 78.38 ± 13.32 μM in shYTHDC1‐1 and 85.98 ± 12.35 μM in shYTHDC1‐2 T24 cells (Figure 2H), and increased from 19.42 ± 5.11 μM in shNC cells to 42.30 ± 4.85 μM in shYTHDC1‐1 and 43.78 ± 4.03 μM in shYTHDC1‐2 U3 cells (Figure 2I).